Vanda Pharmaceuticals (VNDA) Interest Expenses (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted Interest Expenses of $7.9 million for Q1 2026, up 194.59% sequentially from $2.7 million in Q4 2025, and up 13.43% YoY from $7.0 million in Q1 2025.
Vanda Pharmaceuticals (VNDA) Interest Expenses (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported Interest Expenses for 17 years, with the latest figure at $7.9 million in Q1 2026.
- Quarterly Interest Expenses rose 13.43% year-over-year to $7.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.9 million (up 13.43% YoY) and the FY2025 annual result came in at $124.4 million, up 1299.81% from the prior year.
- Interest Expenses improved to $7.9 million in Q1 2026 per VNDA's latest filing, from $2.7 million in the prior quarter.
- Over five years, Interest Expenses peaked at $8.9 million in Q4 2024 and troughed at $1.5 million in Q3 2023.
- A 5-year average of $5.3 million and a median of $7.0 million in 2024 frame the typical range for Interest Expenses.
- The sharpest annual moves came in 2022 and 2024: Interest Expenses tumbled 91.56% in 2022, then soared 378.95% in 2024.
- Over 5 years, Interest Expenses stood at $7.1 million in 2022, then gained by 19.77% to $8.5 million in 2023, then climbed by 3.98% to $8.9 million in 2024, then plunged by 69.64% to $2.7 million in 2025, then soared by 194.59% to $7.9 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $7.9 million, $2.7 million, and $7.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Vanda Pharmaceuticals | 315.57 Mn | 145.54 Mn | 46.97 Mn | 7.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.95 Mn |
| Jun 30, 2026 | 7.95 Mn |
| Mar 31, 2026 | 7.95 Mn |
| Mar 31, 2026 | 7.95 Mn |
| Dec 31, 2025 | 2.70 Mn |
| Dec 31, 2025 | 2.70 Mn |
| Sep 30, 2025 | 7.01 Mn |
| Sep 30, 2025 | 7.01 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 7.01 Mn |
| Mar 31, 2025 | 7.01 Mn |
| Dec 31, 2024 | 8.89 Mn |
| Dec 31, 2024 | 8.89 Mn |
| Sep 30, 2024 | 7.01 Mn |
| Sep 30, 2024 | 7.01 Mn |
| Jun 30, 2024 | 7.01 Mn |
| Jun 30, 2024 | 7.01 Mn |
| Mar 31, 2024 | 7.01 Mn |
| Mar 31, 2024 | 7.01 Mn |